NAD Infusion Is Not Proven Safe or Effective for Clinical Use
Direct intravenous NAD+ infusion lacks robust evidence for safety and efficacy and should not be recommended outside of research protocols. The available evidence consists primarily of low-quality observational studies and commercial wellness center data, with no FDA approval for therapeutic NAD+ infusion.
Critical Evidence Gaps
Lack of Regulatory Approval
The FDA labeling for NAD+ products 1 indicates approval only for external topical use, explicitly warning "For external use only, not to be swallowed" and "In case of accidental ingestion, seek professional assistance." This is fundamentally a cosmetic dermatologic product 1, not an approved intravenous therapeutic agent.
Guideline Context: NAD as a Metabolite, Not a Drug
The ESPEN micronutrient guidelines 2 discuss NAD exclusively as the metabolically active form derived from niacin (vitamin B3) supplementation—not as a direct infusion product. The guidelines specify:
- Niacin converts to NAD in tissues through normal metabolism
- Parenteral nutrition should provide 40 mg/day of niacin 2
- Pediatric PN provides 4-6.8 mg/kg/day niacin 3
These are physiologic doses of the precursor (niacin), not direct NAD+ infusions at pharmacologic doses.
Safety Concerns from Available Data
Significant Tolerability Issues
A 2026 retrospective study 4 comparing NAD+ IV versus nicotinamide riboside (NR) IV in a commercial wellness setting revealed:
NAD+ IV caused:
- Moderate to severe gastrointestinal symptoms
- Increased heart rate during infusion
- Chest pressure
- Average infusion time of 97 minutes (vs. 37 minutes for NR)
- Required slower administration due to symptom severity
In contrast, NR IV caused only:
- Minor tingling sensations
- Mild cramping
- All symptoms resolved immediately post-infusion
Lack of Long-Term Safety Data
The retrospective study 4 followed patients for only 30 days with no significant changes in liver enzymes (ALT, AST) or inflammatory markers (hsCRP). However:
- Sample size was small
- No control group
- Commercial setting without rigorous monitoring
- No assessment of repeated long-term use
Efficacy Evidence Is Insufficient
Substance Use Disorder Study
A 2022 study 5 claimed benefits for addiction treatment but had critical limitations:
- Open-label design (no blinding or placebo control)
- Subjective Likert-scale outcomes
- Combined NAD with enkephalinase inhibitors (confounding intervention)
- No long-term follow-up beyond treatment period
- High risk of bias
Parkinson's Disease Study
A 1993 open-label trial 6 in 885 Parkinson's patients reported 80% response rate, but:
- No placebo control (massive placebo effect in Parkinson's)
- Published over 30 years ago
- Never replicated in controlled trials
- Lacks modern methodological standards
Metabolic Outcomes Are Inconsistent
The 2026 tolerability study 4 showed:
- NR IV reduced HbA1c (exploratory finding)
- NAD+ IV reduced HDL-C (potentially harmful)
- No changes in fasting glucose or LDL-C
- These exploratory findings are hypothesis-generating only
Clinical Recommendation Algorithm
When patients inquire about NAD+ infusions:
Explain the evidence gap: No FDA approval for IV use; only topical cosmetic approval exists
Address underlying concerns: Identify what condition they're trying to treat
Offer evidence-based alternatives:
- For niacin deficiency/pellagra: Oral niacin 15-20 mg/day or nicotinamide 300 mg/day 2
- For general wellness: Balanced diet with niacin-rich foods (meat, fish, fortified grains)
- For specific conditions: Treat according to established guidelines
If deficiency is suspected: Measure urinary niacin metabolites (NMN, 2-Pyr) or erythrocyte NAD levels 2
Avoid commercial wellness infusions: The risk-benefit ratio is unfavorable given:
- Significant infusion-related symptoms
- Lack of proven benefit
- Potential for harm (HDL reduction, cardiovascular effects)
- High cost without insurance coverage
Common Pitfalls to Avoid
- Don't confuse NAD+ precursors with NAD+ itself: Oral niacin/nicotinamide riboside supplements have different pharmacokinetics and safety profiles than IV NAD+
- Don't rely on wellness center marketing: Commercial settings lack rigorous safety monitoring and have financial conflicts of interest
- Don't assume "natural" means safe: NAD+ infusions cause significant cardiovascular and GI symptoms during administration
- Don't extrapolate from animal studies: Recent research in silkworms 7 and mice 8, 9 cannot justify human clinical use
The burden of proof for safety and efficacy has not been met for NAD+ infusions. Until high-quality randomized controlled trials demonstrate benefit without harm, this intervention should remain investigational only.